These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 22370302)

  • 1. [Effects of parathyroid hormone on bone metabolism : differences between intermittent and continuous treatment].
    Ishizuya T
    Clin Calcium; 2012 Mar; 22(3):357-63. PubMed ID: 22370302
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Treatment of osteoporosis with PTH].
    Takeuchi Y
    Clin Calcium; 2014 Jun; 24(6):893-902. PubMed ID: 24870841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effects of parathyroid hormone (teriparatide) on bone quality in osteoporosis].
    Saito M; Marumo K
    Clin Calcium; 2012 Mar; 22(3):343-55. PubMed ID: 22370301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Anabolic action of PTH under the loading/unloading condition].
    Sakai A
    Clin Calcium; 2012 Mar; 22(3):365-71. PubMed ID: 22370303
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Infrequent delivery of a long-acting PTH-Fc fusion protein has potent anabolic effects on cortical and cancellous bone.
    Kostenuik PJ; Ferrari S; Pierroz D; Bouxsein M; Morony S; Warmington KS; Adamu S; Geng Z; Grisanti M; Shalhoub V; Martin S; Biddlecome G; Shimamoto G; Boone T; Shen V; Lacey D
    J Bone Miner Res; 2007 Oct; 22(10):1534-47. PubMed ID: 17576164
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short-term continuous infusion of human parathyroid hormone 1-34 fragment is catabolic with decreased trabecular connectivity density accompanied by hypercalcemia in C57BL/J6 mice.
    Iida-Klein A; Lu SS; Kapadia R; Burkhart M; Moreno A; Dempster DW; Lindsay R
    J Endocrinol; 2005 Sep; 186(3):549-57. PubMed ID: 16135674
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Therapeutic agents for disorders of bone and calcium metabolism--Teriparatide, parathyroid hormone (1-34) as a daily subcutaneous injection].
    Hashimoto Y; Wakayama N; Miyauchi A
    Clin Calcium; 2007 Jan; 17(1):48-55. PubMed ID: 17211093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bone response to intermittent parathyroid hormone is altered in mice null for {beta}-Arrestin2.
    Ferrari SL; Pierroz DD; Glatt V; Goddard DS; Bianchi EN; Lin FT; Manen D; Bouxsein ML
    Endocrinology; 2005 Apr; 146(4):1854-62. PubMed ID: 15705780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of dosing frequency of teriparatide (PTH 1-34) on bone formation in rats: comparison of bone metabolism marker levels.
    Watanabe A; Tsurui K; Yoneyama S; Iwata H; Anzai T; Jerome C; Nakae D
    J Toxicol Sci; 2018; 43(7):435-442. PubMed ID: 29973475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Arrestins in bone.
    Bohinc BN; Gesty-Palmer D
    Prog Mol Biol Transl Sci; 2013; 118():335-58. PubMed ID: 23764060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Parathyroid hormone and its effects on dental tissues.
    Aggarwal P; Zavras A
    Oral Dis; 2012 Jan; 18(1):48-54. PubMed ID: 21895887
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigational parathyroid hormone receptor analogs for the treatment of osteoporosis.
    Polyzos SA; Makras P; Efstathiadou Z; Anastasilakis AD
    Expert Opin Investig Drugs; 2015 Feb; 24(2):145-57. PubMed ID: 25316089
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Bone Cell Biology Assessed by Microscopic Approach. The effect of parathyroid hormone and teriparatide on bone].
    Takahata M
    Clin Calcium; 2015 Oct; 25(10):1529-35. PubMed ID: 26412733
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Anabolic action of teriparatide to osteoporotic patients].
    Hasegawa T; Miyamoto Y; Yamamoto T; Amizuka N
    Nihon Yakurigaku Zasshi; 2019; 153(1):16-21. PubMed ID: 30643087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intermittent PTH (1-34) injection rescues the retarded skeletal development and postnatal lethality of mice mimicking human achondroplasia and thanatophoric dysplasia.
    Xie Y; Su N; Jin M; Qi H; Yang J; Li C; Du X; Luo F; Chen B; Shen Y; Huang H; Xian CJ; Deng C; Chen L
    Hum Mol Genet; 2012 Sep; 21(18):3941-55. PubMed ID: 22634226
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The roles of parathyroid hormone in bone remodeling: prospects for novel therapeutics.
    Lombardi G; Di Somma C; Rubino M; Faggiano A; Vuolo L; Guerra E; Contaldi P; Savastano S; Colao A
    J Endocrinol Invest; 2011 Jul; 34(7 Suppl):18-22. PubMed ID: 21985975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Parathyroid hormone increases the concentration of insulin-like growth factor-I and transforming growth factor beta 1 in rat bone.
    Pfeilschifter J; Laukhuf F; Müller-Beckmann B; Blum WF; Pfister T; Ziegler R
    J Clin Invest; 1995 Aug; 96(2):767-74. PubMed ID: 7635970
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anabolic actions of PTH (1-34): use of a novel tissue engineering model to investigate temporal effects on bone.
    Pettway GJ; Schneider A; Koh AJ; Widjaja E; Morris MD; Meganck JA; Goldstein SA; McCauley LK
    Bone; 2005 Jun; 36(6):959-70. PubMed ID: 15878317
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Studies on the mechanisms of the skeletal anabolic action of endogenous and exogenous parathyroid hormone.
    Goltzman D
    Arch Biochem Biophys; 2008 May; 473(2):218-24. PubMed ID: 18358824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Teriparatide: human recombinant parathyroid hormone (1-34) as a daily subcutaneous injection].
    Sowa H; Hamaya E; Yamamoto T
    Clin Calcium; 2011 Jan; 21(1):9-16. PubMed ID: 21187589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.